Home Tags BDC-1001

Tag: BDC-1001

Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement

ADC Review | Editorial Team
Piramal Pharma Solutions, a contract development and manufacturing organization (CDMO) and San Francisco-based biotech Bolt Bioterapeutics have signed a production agreement in which Piramal...

U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a...

ADC Review | Editorial Team
San Francisco Bay Area-based Bolt Biotherapeutics confirmed that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,675,358 entitled "Antibody Adjuvant...

How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads...

Jon Gingrich
Antibody-drug Conjugates or ADCs combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise, targeted, therapeutic applications. Combining the...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X